Tag: revance therapeutics

All

Revance Reports Q4 and Full Year 2021 Financial Results; Credits Dermal Filler Sales for Growth

The company also announced progress on its DaxibotulinumtoxinA for Injection for glabellar lines and intent to launch the RHA Redensity dermal filler in the second half of 2022.

Revance Resubmits BLA to FDA for DaxibotulinumtoxinA for Injection
Revance Closes on $300M Note Purchase Agreement with Athyrium Capital Management
FDA Accepts Revance Resubmission for Frown Line Treatment
FDA Approves Revance Daxxify for Frown Lines
Studies Show Efficacy of Daxxify to Treat Frown Lines
Revance Publishes 2 Papers on Daxxify Injectable

All

Sorry, No Posts Found

All

GC Aesthetics Unveils MDR-Approved Breast Implant

GC Aesthetics has introduced Luna XT, the inaugural breast implant approved under the new European Medical Device Regulation, emphasizing enhanced safety amid increasing breast reconstruction surgeries.

Are Your Employees About to Quit?
Aesthetic Procedures Risky in Unregulated Offices, Warns Society
ASPS Highlights Commitment to Patient Safety Amid Cosmetic Surgery Concerns